Critical review of EU BE guideline (Rev.1) [Regulatives / Guidelines]
Dear all!
I have another one:
4.1.1 Study design, Alternative designs, page 5/6 (lines 163-169)
'A multiple dose study as an alternative to single dose may also be acceptable if problems of sensitivity of the analytical method precludes sufficiently precise plasma concentration measurements after single dose administration. As Cmax at steady state may be less sensitive to differences in the absorption rate than Cmax after single dose, bioequivalence should, if possible, be determined for Cmax after single dose administration (i.e. after the first dose [...]).
The last sentence excludes one of the possibilities for dealing with HVD's, namly a steady state study to reduce variability in Cmax in comparision to the single dose variability (if this is possible for the formulation under consideration).
It is required by this sentence that the whole concentration time course of the first dose has to be followed up by a sufficient sampling schedule.
This is in practice essentially the request of doing two studies: single dose and multiple dose, although combined.
It remains the secret of the authors of this DRAFT why the first dose Cmax should be a suitable metric or should be better in detecting differences in case of "... problems of sensitivity of the analytical method precludes sufficiently precise plasma concentration measurements after single dose administration ..."
I have another one:
4.1.1 Study design, Alternative designs, page 5/6 (lines 163-169)
'A multiple dose study as an alternative to single dose may also be acceptable if problems of sensitivity of the analytical method precludes sufficiently precise plasma concentration measurements after single dose administration. As Cmax at steady state may be less sensitive to differences in the absorption rate than Cmax after single dose, bioequivalence should, if possible, be determined for Cmax after single dose administration (i.e. after the first dose [...]).
The last sentence excludes one of the possibilities for dealing with HVD's, namly a steady state study to reduce variability in Cmax in comparision to the single dose variability (if this is possible for the formulation under consideration).
It is required by this sentence that the whole concentration time course of the first dose has to be followed up by a sufficient sampling schedule.
This is in practice essentially the request of doing two studies: single dose and multiple dose, although combined.
It remains the secret of the authors of this DRAFT why the first dose Cmax should be a suitable metric or should be better in detecting differences in case of "... problems of sensitivity of the analytical method precludes sufficiently precise plasma concentration measurements after single dose administration ..."
—
Regards,
Detlew
Regards,
Detlew
Complete thread:
- Critical review of EU BE guideline (Rev.1) Helmut 2008-08-22 14:30 [Regulatives / Guidelines]
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-22 15:42
- Critical review of EU BE guideline (Rev.1) Helmut 2008-08-23 02:02
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-25 09:14
- Variations Helmut 2008-08-25 11:06
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-25 09:14
- Critical review of EU BE guideline (Rev.1) Helmut 2008-08-23 02:02
- Critical review of EU BE guideline (Rev.1) Jaime_R 2008-08-23 16:47
- Critical review of EU BE guideline (Rev.1) Ravi 2008-08-25 08:19
- Two Stage Design Helmut 2008-08-25 11:43
- Two Stage Design JPL 2008-08-28 09:44
- Two Stage Design Helmut 2008-08-28 11:50
- Two Stage Design d_labes 2008-08-28 12:09
- Sequential Design Helmut 2008-11-05 13:22
- Two Stage Design Helmut 2008-08-28 11:50
- Two Stage Design JPL 2008-08-28 09:44
- Two Stage Design Helmut 2008-08-25 11:43
- Critical review of EU BE guideline (Rev.1) banusunman 2008-08-26 16:56
- Washout Helmut 2008-10-15 16:02
- Critical review of EU BE guideline (Rev.1) Ravi 2008-08-25 08:19
- Critical review of EU BE guideline (Rev.1)d_labes 2008-08-25 09:49
- Critical review of EU BE guideline (Rev.1) Helmut 2008-08-25 12:11
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-25 13:03
- Urban legend? Helmut 2008-11-21 16:06
- Urban legend? d_labes 2008-11-24 15:06
- Critical review of EU BE guideline (Rev.1) Helmut 2008-08-25 12:11
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-25 11:16
- Critical review of EU BE guideline (Rev.1), tmax, MRT, LZ d_labes 2008-08-25 11:32
- Critical review of EU BE guideline (Rev.1), tmax, MRT, LZ Helmut 2008-08-25 13:10
- tmax, nonparametrics Helmut 2008-10-13 15:38
- tmax, nonparametrics d_labes 2008-10-14 08:33
- tmax, nonparametrics Helmut 2008-10-14 11:29
- tmax, Canadian approach Helmut 2008-11-21 15:41
- tmax, Canadian approach d_labes 2008-11-24 13:53
- Early exposure, Canadian approach: GMR only! Helmut 2009-02-08 00:44
- Early exposure, Canadian approach: GMR only! d_labes 2009-02-09 08:50
- Early exposure, Canadian approach: GMR only! Helmut 2009-02-08 00:44
- tmax; another example Helmut 2008-12-25 15:59
- tmax, Canadian approach d_labes 2008-11-24 13:53
- tmax, nonparametrics d_labes 2008-10-14 08:33
- Automatic integration janmacek 2008-08-27 12:21
- Automatic integration Ohlbe 2008-08-27 14:49
- Manual reintegration! H_Rotter 2008-08-28 11:28
- Manual reintegration! ElMaestro 2008-08-28 12:44
- Manual reintegration! H_Rotter 2008-08-28 11:28
- Automatic integration Ohlbe 2008-08-27 14:49
- Subject accountability, Proc MIXED or equivalent d_labes 2008-09-02 11:13
- Subject accountability, Proc MIXED or equivalent Ohlbe 2008-09-02 15:20
- Subject accountability, Proc MIXED or equivalent d_labes 2008-09-02 16:30
- Subject accountability, Proc MIXED or equivalent Ohlbe 2008-09-02 15:20
- partial AUC, early exposure d_labes 2008-09-03 08:35
- HVDs? Helmut 2008-09-23 12:52
- HVDs? d_labes 2008-09-23 14:20
- HVDs? Helmut 2009-01-20 14:33
- E.g., omeprazole Helmut 2009-03-06 17:21
- BCS-based Biowaiver Helmut 2008-09-25 15:48
- Dissolution update Helmut 2008-10-13 12:43
- EUFEPS workshop Helmut 2008-12-23 17:03
- Critical review of EU BE guideline (Rev.1) d_labes 2008-08-22 15:42